gestodene
Trade name: Femodene
Small moleculeexperimental
Gestodene, sold under the brand names Femodene and Minulet among others, is a progestin medication which is used in birth control pills for women. It is also used in menopausal hormone therapy. The medication is available almost exclusively in combination with an estrogen. It is taken by mouth. — Wikipedia
Clinical trial activity
17 trials · 12 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
9
Phase 3
3
Phase 4
3
Earliest trial started Nov 1, 2004 (NCT00185354)
Timeline
Indications
Approved for
Mechanism of action
- Progesterone receptorAGONIST
PGR agonist
Chemistry & pharmacology
Loading structure…
SMILES
C#C[C@]1(O)C=C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21CC- Mol. weight
- 310.44 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaGestodene ↗
- ChEMBLCHEMBL1213583 ↗
Also known as
- 13-ethyl-17-hydroxy-18,19-dinor-17 alpha-pregna-4,15-dien-20-yn-3-one
- 17-alpha-ethinyl-13-ethyl-17 beta-hydroxy-4,15-gonadien-3-one
- 18,19-dinorpregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-, (17-alpha)-
- gestinol
- gestoden
- gestoden
- gestoden
- gestodene
- gestodene
- gestodene
- gestodene
- gestodene
- gestodene
- gestodene
- gestodene
- gestodene, ((17alpha)-(+-))-isomer
- gestodeno
- gestodeno
- gestodenum
- gestodenum
- sh b 331
- sh b 331
- sh b 331
- sh b 3331
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06396208 | N/A | May 1, 2024 | Chulalongkorn University |
| NCT06396221 | N/A | May 1, 2024 | Chulalongkorn University |
| NCT04899778 | Phase 4 | Aug 31, 2021 | Cedars-Sinai Medical Center |
| NCT03890042 | N/A | Mar 1, 2019 | Assiut University |
| NCT03881904 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2017 | Ain Shams University |
| NCT03531437 | Phase 4 | Mar 31, 2016 | Mahidol University |
| NCT01260805 | Phase 1 | Sep 1, 2010 | Pfizer |
| NCT00896571 | Phase 2 | Jul 1, 2009 | Bayer |
| NCT00915915 | Phase 2 | Jun 1, 2009 | Bayer |
| NCT00984789 | Phase 3 | May 1, 2009 | Bayer, Parexel |
| NCT00873483 | Phase 2 | Apr 1, 2009 | Bayer |
| NCT00914693 | Phase 3 | Apr 1, 2009 | Bayer |
| NCT00729404 | Phase 2 | Aug 1, 2008 | Bayer |
| NCT00517556 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2007 | Pennsylvania State University |
| NCT01056042 | Phase 4 | Jun 1, 2007 | Prince of Songkla University |
| NCT01372293 | N/A | Jan 1, 2005 | Conselho Nacional de Desenvolvimento Científico e Tecnológico, Federal University of Rio Grande do Sul |
| NCT00185354 | Phase 3 | Nov 1, 2004 | Bayer |
Showing 17 of 17 trials
Page 1 / 1
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bayer | For profit | 7 | 7 | 2 | 2004 |
| Chulalongkorn University | Academic/Hospital | 2 | 2 | 1 | 2024 |
| Ain Shams University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Assiut University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Cedars-Sinai Medical Center | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Conselho Nacional de Desenvolvimento Científico e Tecnológico | Government | 1 | 0 | 1 | 2005 |
| Federal University of Rio Grande do Sul | Academic/Hospital | 1 | 1 | 1 | 2005 |
| Mahidol University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Parexel | For profit | 1 | 0 | 1 | 2009 |
| Pennsylvania State University | Academic/Hospital | 1 | 1 | 1 | 2007 |
| Pfizer | For profit | 1 | 1 | 1 | 2010 |
| Prince of Songkla University | Academic/Hospital | 1 | 1 | 1 | 2007 |
12 organizations
Page 1 / 1